ETBX-051 is under clinical development by ImmunityBio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ETBX-051’s likelihood of approval (LoA) and phase transition for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 16 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ETBX-051 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ETBX-051 overview

ETBX-051 is under development for the prevention of castration resistant prostate cancer. The vaccine candidate is a multivalent adenovirus [Ad5 (E1-,E2b- )] based vaccine containing various fused antigens of the A and B strains of influenza. It is administered subcutaneously. This vaccine is developed by utilizing Adenovirus Vector Vaccines (AVVP) technology. It was also under development for pandemic H1N1 influenza.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

Quick View ETBX-051 LOA Data

Report Segments
  • Innovator
Drug Name
  • ETBX-051
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.